Skip to main content

Table 3 Cox univariate and multivariable analysis for recurrence free period (RFP) for combined expression of MIC-AB and ULBP-2.

From: NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study

Relapse Free Period   UNIVARIATE MULTIVARIATE
  N HR 95% CI p-value HR 95% CI p-value
Age        
< 40 48 1.00   0.422    
40-50 145 0.97 0.612-1.539     
50-60 132 1.17 0.734-1.853     
> 60 249 0.90 0.574-1.408     
Grade        
I 80 1.00   0.001 1.00   0.473
II 282 1.43 0.945-2.172   1.18 0.711-1.948  
III 203 2.02 1.326-3.078   1.34 0.802-2.231  
Histological type        
Ductal 513 1.00   0.291    
Other 53 1.24 0.832-1.846     
Tumor stage        
pT1 211 1.00   < 0.001 1.00   0.298
pT2 272 1.59 1.205-2.093   1.17 0.832-1.637  
pT3/4 72 2.49 1.706-3.635   1.45 0.908-2.316  
Nodalstage        
pN- 307 1.00   < 0.001 1.00   < 0.001
pN+ 250 3.06 2.379-3.945   2.70 1.987-3.669  
ER-status        
Negative 203 1.00   0.725    
Positive 337 1.05 0.808-1.359     
PgR-status        
Negative 223 1.00   0.744    
Positive 313 0.96 0.743-1.236     
HER2        
No overexpression 378 1.00   0.401    
Overexpression 44 1.21 0.776-1.883     
Endocrine therapy        
ET- 481 1.00   0.197    
ET+ 93 1.24 0.896-1.705     
Chemotherapy        
CT- 444 1.00   0.839    
CT+ 130 0.97 0.730-1.291     
MIC-AB & ULBP-2        
Both Low 68 1.00   < 0.001 1.00   < 0.001
Either one high 275 0.59 0.426-0.820   0.54 0.380-0.757  
Both high 64 0.38 0.230-0.612   0.41 0.246-0.682  
  1. Missing values are not shown.
  2. AbbreviationsN number of patients; HR hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor receptor 2; ET endocrine therapy; CT chemotherapy.